Experienced in Astrocytoma

Dr. Daniel L. Spitz

Oncology | Hematology
Florida Cancer Specialists And Research Institute, LLC
4801 S Congress Ave, Suite 400, 
Lake Worth, FL 
Accepting New Patients
Offers Telehealth
Experienced in Astrocytoma
Florida Cancer Specialists And Research Institute, LLC
4801 S Congress Ave, Suite 400, 
Lake Worth, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel Spitz is an Oncologist and a Hematologist in Lake Worth, Florida. Dr. Spitz is rated as an Experienced provider by MediFind in the treatment of Astrocytoma. His top areas of expertise are Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, Testicular Yolk Sac Tumor, Sertoli-Leydig Cell Tumor, and Bone Marrow Aspiration. Dr. Spitz is currently accepting new patients.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in FL
Hospital Affiliations
Wellington Regional Medical Center
Jupiter Medical Center
Good Samaritan Medical Center
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
4801 S Congress Ave, Suite 400, Lake Worth, FL 33461
Other Locations
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
5130 Linton Blvd, Suite B4, Delray Beach, FL 33484
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
1309 N Flagler Dr, Florida Cancer Specialists, West Palm Beach, FL 33401
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
2848 Ctr Pointe Dr, Fl 1, Fort Myers, FL 33916
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
3401 Pga Blvd, Suite 200, Palm Beach Gardens, FL 33410
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
1037 S State Rd 7, 303 Florida Cancer Special, Wellington, FL 33414
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
1970 Golf St, Sarasota, FL 34236

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, AB680, Enzalutamide, Docetaxel
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
Enrollment Status: Completed
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 2
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 3
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
Enrollment Status: Completed
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drugs: Entinostat, Avelumab
Study Phase: Phase 1/Phase 2
A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
Enrollment Status: Terminated
Publish Date: February 21, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

5 Total Publications

Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
Journal: Gynecologic oncology
Published: May 13, 2024
Similar Doctors
Distinguished in Astrocytoma
Dr. Atif M. Hussein
Hematology Oncology | Hematology | Oncology
Distinguished in Astrocytoma
Dr. Atif M. Hussein
Hematology Oncology | Hematology | Oncology

South Broward Hospital District

1150 N 35 Ave, 
Hollywood, FL 
 (40.8 miles away)
Languages Spoken:
English, Arabic, Creoles And Pidgins, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Atif Hussein is a Hematologist Oncology specialist and a Hematologist in Hollywood, Florida. Dr. Hussein is rated as a Distinguished provider by MediFind in the treatment of Astrocytoma. His top areas of expertise are Cerebral Ventricle Cancer, Angiosarcoma, Astrocytoma, and Atypical Teratoid Rhabdoid Tumor (ATRT). Dr. Hussein is currently accepting new patients.

Advanced in Astrocytoma
Dr. Dionysios C. Watson
Oncology
Advanced in Astrocytoma
Dr. Dionysios C. Watson
Oncology

University Of Miami

1192 E Newport Ctr Dr, Uhealth Sylvester At Deerf, 
Deerfield Beach, FL 
 (21.1 miles away)
305-585-8574
Languages Spoken:
English, Greek
See accepted insurances
Accepting New Patients
Offers Telehealth

Dionysios Watson is an Oncologist in Deerfield Beach, Florida. Dr. Watson is rated as an Experienced provider by MediFind in the treatment of Astrocytoma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri. Dr. Watson is currently accepting new patients.

Jose Lutzky
Experienced in Astrocytoma
Dr. Jose Lutzky
Hematology | Oncology
Experienced in Astrocytoma
Dr. Jose Lutzky
Hematology | Oncology

University Of Miami

2801 Ne 213th St, 1101 Aventura Medical Cent, 
Miami, FL 
 (43.8 miles away)
305-585-6226
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jose Lutzky is a Hematologist and an Oncologist in Miami, Florida. Dr. Lutzky is rated as a Distinguished provider by MediFind in the treatment of Astrocytoma. His top areas of expertise are Melanoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Uveal Melanoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Spitz's expertise for a condition
ConditionClose
    View All 36 Advanced Conditions
    View All 113 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile